One-stop PROLASTIN-C enrollment, delivery and support

Prolastin Direct® Patient Services secures insurance authorization, coordinates infusion services, ships PROLASTIN-C directly to the location of your choice, and connects you to health management coordinators who are experienced Alpha-1 patients themselves. Find out more about Prolastin Direct® Patient Services now

The Benefits of PROLASTIN-C Therapy

Since 1988, patients treated with PROLASTIN® have achieved target AAT levels in as little as 1 month.2

PROLASTIN-C is augmentation therapy

PROLASTIN-C is called augmentation therapy; it "augments" or replaces the AAT missing from your body. The effect of augmentation therapy on pulmonary exacerbations and on the rate of progression of emphysema has not been demonstrated in adequately powered, randomized, controlled clinical trials for any Alpha1-PI product.

In clinical trials, PROLASTIN-C was as effective as PROLASTIN at raising AAT levels.

PROLASTIN-C is only approved for chronic or "ongoing" augmentation and maintenance therapy in people with genetic emphysema caused by AAT deficiency. PROLASTIN-C is not approved for the treatment of emphysema due to other causes.1 PROLASTIN-C is not indicated for treatment of liver disease due to Alpha-1.

The most common drug-related adverse reactions observed included chills, malaise, headache, rash, hot flush and pruritus. The most serious adverse reaction observed during clinical studies was an abdominal and extremity rash in one subject.

PROLASTIN-C provides important patient conveniences

  • Shorter infusion volume and time compared to PROLASTIN
  • approximately 15-minute infusion time when given at the recommended infusion rate
  • Easy product storage
  • no refrigeration needed

next: Dosage & Administration of PROLASTIN-C >

Important Safety Information
Prolastin-C, Alpha1-Proteinase Inhibitor (Human) is for adults who have emphysema caused by inherited alpha1-antitrypsin deficiency. The effect of therapy with any alpha1-proteinase inhibitor (alpha1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Prolastin-C may contain trace amounts of IgA. IgA deficient patients with antibodies against IgA should not receive Prolastin-C due to the risk of hypersensitivity.

The most common side effects during clinical trials with Prolastin-C were chills, a general feeling of being unwell, headache, rash, hot flush, and itching.

Prolastin-C is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying Prolastin-C Full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References
  1. PROLASTIN-C [package insert]. Talecris Biotherapeutics.
  2. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055-1062.